{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:48:51Z","timestamp":1790711331714,"version":"4.1.0"},"reference-count":78,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The glycoprotein disorders are a group of lysosomal storage diseases (\u03b1-mannosidosis, aspartylglucosaminuria, \u03b2-mannosidosis, fucosidosis, galactosialidosis, sialidosis, mucolipidosis II, mucolipidosis III, and Schindler Disease) characterized by specific lysosomal enzyme defects and resultant buildup of undegraded glycoprotein substrates. This buildup causes a multitude of abnormalities in patients including skeletal dysplasia, inflammation, ocular abnormalities, liver and spleen enlargement, myoclonus, ataxia, psychomotor delay, and mild to severe neurodegeneration. Pharmacological treatment options exist through enzyme replacement therapy (ERT) for a few, but therapies for this group of disorders is largely lacking. Hematopoietic cell transplant (HCT) has been explored as a potential therapeutic option for many of these disorders, as HCT introduces functional enzyme-producing cells into the bone marrow and blood along with the engraftment of healthy donor cells in the central nervous system (presumably as brain macrophages or a type of microglial cell). The outcome of HCT varies widely by disease type. We report our institutional experience with HCT as well as a review of the literature to better understand HCT and outcomes for the glycoprotein disorders.<\/jats:p>","DOI":"10.3390\/cells9061411","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:34:16Z","timestamp":1591684456000},"page":"1411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases"],"prefix":"10.3390","volume":"9","author":[{"given":"Brianna M.","family":"Naumchik","sequence":"first","affiliation":[{"name":"Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-5533","authenticated-orcid":false,"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Flanagan-Steet","sequence":"additional","affiliation":[{"name":"Greenwood Genetic Center, Greenwood, SC 29646, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-4963","authenticated-orcid":false,"given":"Richard A.","family":"Steet","sequence":"additional","affiliation":[{"name":"Greenwood Genetic Center, Greenwood, SC 29646, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Cathey","sequence":"additional","affiliation":[{"name":"Greenwood Genetic Center, Greenwood, SC 29646, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[{"name":"Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/geno.1997.4668","article-title":"Genomic structure of the human lysosomal alpha-mannosidase gene (MANB)","volume":"42","author":"Riise","year":"1997","journal-title":"Genomics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0378-1119(97)00337-5","article-title":"Characterization of the human MANB gene encoding lysosomal alpha-D-mannosidase","volume":"198","author":"Wakamatsu","year":"1997","journal-title":"Gene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(67)92303-3","article-title":"Generalised Storage Disorder Resembling Hurlers Syndrome","volume":"290","year":"1967","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-3-21","article-title":"Alpha-mannosidosis","volume":"3","author":"Malm","year":"2008","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1203\/00006450-197810000-00012","article-title":"A new variant of mannosidosis with increased residual enzymatic activity and mild clinical manifestation","volume":"12","author":"Bach","year":"1978","journal-title":"Pediatr. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1203\/00006450-197612000-00008","article-title":"Mannosidosis: Clinical, morphologic, immunologic, and biochemical studies","volume":"10","author":"Desnick","year":"1976","journal-title":"Pediatr. Res."},{"key":"ref_7","first-page":"93","article-title":"The clinical course of mannosidosis","volume":"14","author":"Autio","year":"1982","journal-title":"Ann. Clin. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.bmt.1705550","article-title":"Haematopoietic stem cell transplantation trends in children over the last three decades: A survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation","volume":"39","author":"Miano","year":"2007","journal-title":"Bone Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","article-title":"Cord-blood transplants from unrelated donors in patients with Hurler\u2019s syndrome","volume":"350","author":"Staba","year":"2004","journal-title":"N. Engl J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bmt.2011.99","article-title":"Allogeneic hematopoietic SCT for alpha-mannosidosis: An analysis of 17 patients","volume":"47","author":"Mynarek","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","first-page":"185","article-title":"Alpha-mannosidosis\u2014a review of genetic, clinical findings and options of treatment","volume":"12","author":"Borgwardt","year":"2014","journal-title":"Pediatric Endocrinol. Rev. Per."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/8904_2013_221","article-title":"Cerebral Magnetic Resonance Spectroscopy Demonstrates Long-Term Effect of Bone Marrow Transplantation in alpha-Mannosidosis","volume":"11","author":"Danielsen","year":"2013","journal-title":"Jimd Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF02426460","article-title":"MR findings in mannosidosis","volume":"32","author":"Dietemann","year":"1990","journal-title":"Neuroradiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1212\/01.WNL.0000143057.25471.4F","article-title":"Adult alpha-mannosidosis: Clinical progression in the absence of demyelination","volume":"63","author":"Gutschalk","year":"2004","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10545-011-9331-7","article-title":"Proton nuclear magnetic resonance spectroscopic detection of oligomannosidic n glycans in alpha-mannosidosis: A method of monitoring treatment","volume":"34","author":"Avenarius","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.nbd.2017.07.013","article-title":"Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice","volume":"106","author":"Stroobants","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/acn3.245","article-title":"Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice","volume":"2","author":"Damme","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Adam, J., Malone, R., Lloyd, S., Lee, J., Hendriksz, C.J., and Ramaswami, U. (2019). Disease progression of alpha-mannosidosis and impact on patients and carers\u2014A UK natural history survey. Mol. Genet. Metab. Rep., 20.","DOI":"10.1016\/j.ymgmr.2019.100480"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10545-018-0175-2","article-title":"Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis","volume":"41","author":"Lund","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ceccarini, M.R., Codini, M., Conte, C., Patria, F., Cataldi, S., Bertelli, M., Albi, E., and Beccari, T. (2018). Alpha-Mannosidosis: Therapeutic Strategies. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051500"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: A review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1096\/fasebj.7.13.8405810","article-title":"Aspartylglycosaminuria: Protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation","volume":"7","author":"Mononen","year":"1993","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(05)63202-3","article-title":"Bone-marrow transplantation in aspartylglucosaminuria","volume":"349","author":"Autti","year":"1997","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mpd.2001.110119","article-title":"Bone marrow transplantation for aspartylglucosaminuria: Follow-up study of transplanted and non-transplanted patients","volume":"138","author":"Arvio","year":"2001","journal-title":"J. Pediatrics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007890-200408150-00015","article-title":"Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors","volume":"78","author":"Malm","year":"2004","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.tp.0000181457.43146.36","article-title":"Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single center","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1096\/fasebj.9.5.7896015","article-title":"Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria","volume":"9","author":"Mononen","year":"1995","journal-title":"Faseb. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1096\/fasebj.14.2.361","article-title":"Enzyme replacement therapy in a mouse model of aspartylglycosaminuria","volume":"14","author":"Dunder","year":"2000","journal-title":"Faseb. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10545-010-9158-7","article-title":"Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice","volume":"33","author":"Dunder","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10038-007-0136-3","article-title":"Mutation identification and characterization of a Taiwanese patient with fucosidosis","volume":"52","author":"Lin","year":"2007","journal-title":"J. Hum. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajmg.1320380125","article-title":"Fucosidosis revisited: A review of 77 patients","volume":"38","author":"Willems","year":"1991","journal-title":"Am. J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11011-017-9968-5","article-title":"Brain abnormalities in fucosidosis: Transplantation or supportive therapy?","volume":"32","author":"Jiang","year":"2017","journal-title":"Metab. Brain. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1702994","article-title":"Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation","volume":"27","author":"Miano","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","first-page":"89","article-title":"The clinical effects of lysosomal enzyme replacement by bone marrow transplantation after total lymphoid irradiation on neurologic disease in fucosidase deficient dogs","volume":"20","author":"Taylor","year":"1988","journal-title":"Transpl. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajmg.1320420439","article-title":"Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs","volume":"42","author":"Taylor","year":"1992","journal-title":"Am. J. Med. Genet."},{"key":"ref_36","first-page":"153","article-title":"Allogeneic bone marrow transplantation for fucosidosis","volume":"15","author":"Vellodi","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","first-page":"S66","article-title":"Allogeneic hematopoietic stem transplant improves outcome in fucosidosis","volume":"126","author":"Gupta","year":"2019","journal-title":"Mol. Genet. Metab"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-015-0357-z","article-title":"The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis","volume":"10","author":"Kondagari","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_39","first-page":"2563","article-title":"Long-term follow-up of metachronous marrow-kidney transplantation in severe type II sialidosis: What does success mean?","volume":"20","author":"Schiff","year":"2005","journal-title":"Nephrol. Dial. Transplant.  Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymgme.2019.09.005","article-title":"Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview","volume":"129","author":"Caciotti","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","first-page":"1","article-title":"Sialidosis: A review of human neuraminidase deficiency","volume":"31","author":"Lowden","year":"1979","journal-title":"Am. J. Hum. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2005.03.007","article-title":"Short-term, high dose enzyme replacement therapy in sialidosis mice","volume":"85","author":"Wang","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM198611063151906","article-title":"Human beta-mannosidase deficiency","volume":"315","author":"Wenger","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1096-7192(02)00172-5","article-title":"Variable clinical presentation of lysosomal beta-mannosidosis in patients with null mutations","volume":"77","author":"Bedilu","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lund, T.C., Miller, W.P., Eisengart, J.B., Simmons, K., Pollard, L., Renaud, D.L., Wenger, D.A., Patterson, M.C., and Orchard, P.J. (2019). Biochemical and clinical response after umbilical cord blood transplant in a boy with early childhood-onset beta-mannosidosis. Mol. Genet. Genom. Med., 7.","DOI":"10.1002\/mgg3.712"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.bbmt.2014.06.019","article-title":"Outcomes after hematopoietic stem cell transplantation for children with I-cell disease","volume":"20","author":"Lund","year":"2014","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1242\/dmm.008219","article-title":"Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucolipidosis II","volume":"5","author":"Petrey","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.celrep.2018.02.066","article-title":"TGF-ss Regulates Cathepsin Activation during Normal and Pathogenic Development","volume":"22","author":"Christian","year":"2018","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0024-3205(76)90047-3","article-title":"I-cell disease: Activities of lysosomal enzymes toward natural and synthetic substrates","volume":"19","author":"Wenger","year":"1976","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0022-3476(71)80142-7","article-title":"I-cell disease: A clinical picture","volume":"79","author":"Leroy","year":"1971","journal-title":"J. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.a.32193","article-title":"Molecular order in mucolipidosis II and III nomenclature","volume":"146A","author":"Cathey","year":"2008","journal-title":"Am. J. Med. Genetics. Part. A"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Raas-Rothschild, A., Bargal, R., Goldman, O., Ben-Asher, E., Groener, J.E., Toutain, A., Stemmer, E., Ben-Neriah, Z., Flusser, H., and Beemer, F.A. (2004). Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. J. Med. Genet., 41.","DOI":"10.1136\/jmg.2003.015222"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI5826","article-title":"Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC)","volume":"105","author":"Bao","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"36141","DOI":"10.1074\/jbc.M509008200","article-title":"The alpha- and beta-subunits of the human UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA","volume":"280","author":"Kudo","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10545-018-0186-z","article-title":"Mucolipidosis type III, a series of adult patients","volume":"41","author":"Oussoren","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(88)90999-3","article-title":"Expression of cDNA encoding the human \"protective protein\" associated with lysosomal beta-galactosidase and neuraminidase: Homology to yeast proteases","volume":"54","author":"Galjart","year":"1988","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1073\/pnas.79.15.4535","article-title":"Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man","volume":"79","author":"Hoogeveen","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","first-page":"3811","article-title":"Galactosialidosis","volume":"Volume 3","author":"Scriver","year":"2001","journal-title":"The Metabolic and Molecular Bases of Inherited Disease"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1096-8628(19960823)64:3<453::AID-AJMG2>3.0.CO;2-Q","article-title":"Early-infantile galactosialidosis: Clinical, biochemical, and molecular observations in a new patient","volume":"64","author":"Zammarchi","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/21678707.2016.1266933","article-title":"Galactosialidosis: Historic aspects and overview of investigated and emerging treatment options","volume":"5","author":"Annunziata","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1101\/gad.9.21.2623","article-title":"Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells","volume":"9","author":"Zhou","year":"1995","journal-title":"Genes Dev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14880","DOI":"10.1073\/pnas.95.25.14880","article-title":"Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein\/cathepsin A under control of the colony-stimulating factor-1 receptor promoter","volume":"95","author":"Hahn","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood.V99.9.3169","article-title":"Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells","volume":"99","author":"Leimig","year":"2002","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1096\/fj.03-0941fje","article-title":"Targeting macrophages with baculovirus-produced lysosomal enzymes: Implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis","volume":"18","author":"Bonten","year":"2004","journal-title":"Faseb. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jmg.33.6.458","article-title":"Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: New mutations and the paradox between genotype and phenotype","volume":"33","author":"Keulemans","year":"1996","journal-title":"J. Med. Genet."},{"key":"ref_67","first-page":"804","article-title":"Lysosomal alpha-N-acetylgalactosaminidase deficiency: A new inherited metabolic disease","volume":"2","author":"Schindler","year":"1987","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdermsci.2004.09.005","article-title":"Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): Different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes","volume":"37","author":"Kanekura","year":"2005","journal-title":"J. Derm. Sci"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI114901","article-title":"Schindler disease: The molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy","volume":"86","author":"Wang","year":"1990","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2001.04028.x","article-title":"A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with M\u00e9ni\u00e8re\u2019s syndrome and without mental retardation","volume":"144","author":"Kodama","year":"2001","journal-title":"Br. J. Derm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.biochem.031209.093756","article-title":"From serendipity to therapy","volume":"80","author":"Neufeld","year":"2011","journal-title":"Annu Rev. Biochem"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM198412203112504","article-title":"Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation","volume":"311","author":"Krivit","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","article-title":"Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"2","author":"Hobbs","year":"1981","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/mt.2013.29","article-title":"Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation","volume":"21","author":"Wilkinson","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:36:06Z","timestamp":1760175366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cells9061411"],"URL":"https:\/\/doi.org\/10.3390\/cells9061411","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}